MET and cancer: Pharmaceutically, numerous HGFR and/or MST1R kinase inhibitors have been evaluated for the treatment of different types of cancers, such as Foretinib, BMS-777607, MK-8033, Crizotinib, Cabozantinib (Figure 1).23–25